Raymond James & Associates’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Raymond James & Associates’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14,720	Closed	-$50K	–	3723
2020 Q2	$50K	Buy	+14,720	New	+$69.6K	﹤0.01%	3378
2019 Q3	–	Sell	-12,305	Closed	-$167K	–	3749
2019 Q2	$167K	Buy	12,305 +2,175	+21%	+$25.1K	﹤0.01%	3320
2019 Q1	$55K	Sell	10,130 -1,336	-12%	-$6.5K	﹤0.01%	3468
2018 Q4	$34K	Sell	11,466 -7,200	-39%	-$39.4K	﹤0.01%	3414
2018 Q3	$152K	Buy	18,666 +1,796	+11%	+$13.8K	﹤0.01%	3366
2018 Q2	$164K	Buy	+16,870	New	+$173K	﹤0.01%	3322

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Raymond James & Associates's ZYNE Position: Q3 2020 in Review

Raymond James & Associates sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2020, closing a stake of 14,720 shares — an estimated $50K sold.

Raymond James & Associates first reported a position in ZYNE in Q2 2018 and held it in 6 quarters. The position peaked at $167K in Q2 2019. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2020.

Raymond James & Associates reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
Raymond James & Associates sold 14,720 Zynerba Pharmaceuticals, Inc shares in Q3 2020, an estimated $50K.
Raymond James & Associates first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2018 and held it in 6 quarters.
Raymond James & Associates's Zynerba Pharmaceuticals, Inc position peaked at $167K in Q2 2019.
66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2020.

Based on Raymond James & Associates's 13F filing for Q3 2020, filed 4 Nov 2020.